目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Liver Disease Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis

Chapter 4. Liver Disease Therapeutics Market: Product Business Analysis
4.1. Product Market Share, 2025 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Antiviral Drugs
4.4.1. Antiviral Drugs Market, 2021 - 2033 (USD Million)
4.5. Vaccines
4.5.1. Vaccines Market, 2021 - 2033 (USD Million)
4.6. Chemotherapy
4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
4.7. Targeted Therapy
4.7.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
4.8. Immunosuppressants
4.8.1. Immunosuppressants Market, 2021 - 2033 (USD Million)
4.9. Immunoglobulins
4.9.1. Immunoglobulins Market, 2021 - 2033 (USD Million)
4.10. Corticosteroids
4.10.1. Corticosteroids Market, 2021 - 2033 (USD Million)
4.11. Other Products
4.11.1. Other Products Market, 2021 - 2033 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Business Analysis
5.1. Disease Market Share, 2025 & 2033
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
5.4. Hepatitis
5.4.1. Hepatitis Market, 2021 - 2033 (USD Million)
5.5. Autoimmune Diseases
5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
5.6. Non-alcoholic Fatty Liver Disease (NAFLD)
5.6.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market, 2021 - 2033 (USD Million)
5.7. Cancer
5.7.1. Cancer Market, 2021 - 2033 (USD Million)
5.8. Genetic Disorders
5.8.1. Genetic Disorders Market, 2021 - 2033 (USD Million)
5.9. Other Diseases
5.9.1. Other Diseases Market, 2021 - 2033 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2025 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
6.5.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2017 - 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Gilead Sciences, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. AbbVie Inc.
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Bristol-Myers Squibb Company
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. F. Hoffmann-La Roche Ltd
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Takeda Pharmaceutical Company Limited.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Johnson & Johnson Services, Inc.
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Merck & Co., Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Novartis AG
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Pfizer Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Sanofi
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. GSK plc
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives

List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global liver disease therapeutics market, by region, 2021 - 2033 (USD Million)
Table 4. Global liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 5. Global liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 6. North America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
Table 7. North America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 8. North America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 9. U.S. liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 10. U.S. liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 11. Canada liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 12. Canada liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 13. Mexico liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 14. Mexico liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 15. Europe liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
Table 16. Europe liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 17. Europe liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 18. UK liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 19. UK liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 20. Germany liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 21. Germany liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 22. France liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 23. France liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 24. Italy liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 25. Italy liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 26. Spain liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 27. Spain liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 28. Norway liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 29. Norway liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 30. Denmark liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 31. Denmark liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 32. Sweden liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 33. Sweden liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 34. Asia Pacific liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
Table 35. Asia Pacific liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 36. Asia Pacific liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 37. Japan liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 38. Japan liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 39. China liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 40. China liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 41. India liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 42. India liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 43. Australia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 44. Australia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 45. South Korea liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 46. South Korea liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 47. Thailand liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 48. Thailand liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 49. Latin America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
Table 50. Latin America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 51. Latin America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 52. Brazil liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 53. Brazil liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 54. Argentina liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 55. Argentina liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 56. Middle East & Africa Liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
Table 57. Middle East & Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 58. Middle East & Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 59. South Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 60. South Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 61. Saudi Arabia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 62. Saudi Arabia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 63. UAE liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 64. UAE liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
Table 65. Kuwait liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
Table 66. Kuwait liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)

List of Figures
Fig. 1 Liver disease therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Liver disease therapeutics market dynamics
Fig. 12 Liver disease therapeutics market: Porter’s five forces analysis
Fig. 13 Liver disease therapeutics market: PESTLE analysis
Fig. 14 Product market, 2021 - 2033 (USD Million)
Fig. 15 Antiviral drugs market, 2021 - 2033 (USD Million)
Fig. 16 Vaccines market, 2021 - 2033 (USD Million)
Fig. 17 Chemotherapy market, 2021 - 2033 (USD Million)
Fig. 18 Targeted therapy market, 2021 - 2033 (USD Million)
Fig. 19 Immunosuppressants market, 2021 - 2033 (USD Million)
Fig. 20 Immunoglobulins market, 2021 - 2033 (USD Million)
Fig. 21 Corticosteroids market, 2021 - 2033 (USD Million)
Fig. 22 Other products market, 2021 - 2033 (USD Million)
Fig. 23 Disease market, 2021 - 2033 (USD Million)
Fig. 24 Hepatitis market, 2021 - 2033 (USD Million)
Fig. 25 Autoimmune diseases market, 2021 - 2033 (USD Million)
Fig. 26 Non-alcoholic Fatty Liver Disease (NAFLD) market, 2021 - 2033 (USD Million)
Fig. 27 Cancer market, 2021 - 2033 (USD Million)
Fig. 28 Genetic disorders market, 2021 - 2033 (USD Million)
Fig. 29 Other diseases market, 2021 - 2033 (USD Million)
Fig. 30 Liver disease therapeutics market revenue, by region
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 North America liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 33 U.S. country dynamics
Fig. 34 U.S. liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 35 Canada country dynamics
Fig. 36 Canada liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 37 Mexico country dynamics
Fig. 38 Mexico liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 39 Europe liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 40 UK country dynamics
Fig. 41 UK liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 42 Germany country dynamics
Fig. 43 Germany liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 44 France country dynamics
Fig. 45 France liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 46 Italy country dynamics
Fig. 47 Italy liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 48 Spain country dynamics
Fig. 49 Spain liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 50 Norway country dynamics
Fig. 51 Norway liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 52 Sweden country dynamics
Fig. 53 Sweden liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 54 Denmark country dynamics
Fig. 55 Denmark liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 56 Asia Pacific liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 57 Japan country dynamics
Fig. 58 Japan liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 59 China country dynamics
Fig. 60 China liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 61 India country dynamics
Fig. 62 India liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 63 Australia country dynamics
Fig. 64 Australia liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 65 South Korea country dynamics
Fig. 66 South Korea liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 67 Thailand country dynamics
Fig. 68 Thailand liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 69 Latin America liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 70 Brazil country dynamics
Fig. 71 Brazil liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 72 Argentina country dynamics
Fig. 73 Argentina liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 74 MEA liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 75 South Africa country dynamics
Fig. 76 South Africa liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 77 Saudi Arabia country dynamics
Fig. 78 Saudi Arabia liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 79 UAE country dynamics
Fig. 80 UAE liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 81 Kuwait country dynamics
Fig. 82 Kuwait liver disease therapeutics market, 2021 - 2033 (USD Million)
Fig. 83 Company categorization
Fig. 84 Company market position analysis
Fig. 85 Strategic framework